Emergent BioSolutions Inc. — Director's Dealing 2021

Jan 19, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Emergent BioSolutions Inc. (EBS)
CIK: 0001367644
Period of Report: 2021-01-15

Reporting Person: Kramer Robert (Director, President and CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-01-15	Common Stock	M	19026	$25.62	Acquired	158236	Direct
2021-01-15	Common Stock	S	19026	$106.0076	Disposed	139210	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-01-15	Employee Stock Options (Right to Buy)	$25.62	M	19026	Disposed	2021-03-10	Common Stock (19026.0)	Direct

Footnotes

F1: Consists of an option granted on 03/11/2014 under the company's stock incentive plan as amended and restated.

F2: All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on November 13, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended (the "Exchange Act").

F3: The number of derivative securities beneficially owned was adjusted to account for a change in previously reported PSUs. 8,163 PSUs were previously reported, of which only 5,169 vested on February 11, 2020.

F4: The price reported is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $104.52 to $107.79.